Recurrent Severe Angioedema Associated with Imidapril and Diclofenac  by Kampitak, Thatchai
Allergology International Vol 57, No4, 2008 www.jsaweb.jp 441
Recurrent Severe Angioedema
Associated with Imidapril and
Diclofenac
Thatchai Kampitak1
ABSTRACT
Background: Angioedema due to angiotensin-converting enzyme inhibitors (ACEIs) therapy occurs not infre-
quently and is sometimes associated with life-threatening conditions.
Case Summary: A 59-year-old woman presented with recurrent angioedema of the tongue complicated by
upper airway obstruction which required endotracheal intubation. Laboratory tests including complement levels
were normal. ACEI-associated angioedema precipitated by NSAIDs was suspected. Her condition improved af-
ter discontinuation of imidapril and diclofenac without other specific treatment.
Discussion: ACEIs, and in particular concomitant use with NSAIDs, should be avoided in patients with a his-
tory of angioedema because continuing administration tends to lead to more severe attacks.
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INTRODUCTION
Angioedema is a self-limited, localized swelling that
involves subcutaneous tissue or mucosa, most com-
monly in the periorbital area, perioral area, tongue,
genital area and extremities.1,2 Angioedema may be
classified as hereditary or, more commonly, acquired,
which is usually allergic or idiopathic in origin.2 How-
ever, several drugs have been described as causing
acquired angioedema particularly angiotensin con-
verting enzyme inhibitors.
Angiotensin converting enzyme inhibitors (ACEIs)
are a widely used class of pharmacologic agents indi-
cated in the treatment of hypertension, congestive
heart failure, diabetic nephropathy and have been
widely recognized as a cause of angioedema. Imi-
dapril is one of the most commonly prescribed ACEIs
in Japan and is believed to produce least adverse ef-
fects among ACEIs.3,4 The author reports a case of a
patient with severe recurrent angioedema resulting in
upper airway obstruction in association with imidapril
and diclofenac.
CLINICAL SUMMARY
A 59-year-old female patient with a medical history of
type 2 diabetes, hyperlipidemia, hypertension and
obesity presented with swelling of the tongue and dif-
ficulty in breathing after taking diclofenac to relieve
her knee pain for 2 days. She had no urticaria, fever,
abdominal pain, vomiting or diarrhea.
There was a history of a similar episode which oc-
curred 2 years prior, without concomitant use of
NSAIDs, which required prophylactic nasotracheal
intubation. Her previous medication included
enalapril (which she was administered for a period of
7 years) was discontinued and the symptoms sponta-
neously resolved in a few days without any specific
treatment.
She was later switched to therapy with imidapril for
approximately 2 years. Her other current medications
consisted of glipizide, metformin, fenofibrate,
atenolol, hydrochlorothiazide and nifedipine. She de-
nied any history of smoking, drug rash, seasonal al-
lergies, or previous upper airway surgery.
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PATHOLOGICAL FINDINGS
Laboratory tests including complete blood count,
blood chemistries, and tryptase levels were within
normal limits. Complement levels included the follow-
ing: CH50 41.1 mgdL (19―40), C3 146 mgdL (76−
171) and C4 26.9 mgdL (10―40). Unfortunately, C1
inhibitor (C1-INH) and C1q level could not be meas-
ured. However, their levels are expected to be in the
normal range due to sufficient C4 and CH50 levels.
Therefore, the diagnosis of ACEI-associated angioe-
dema due to imidapril was made by exclusion of
other possible causes including allergic angioedema,
hereditary and acquired angioedema associated with
C1-INH deficiency.
She was prophylactically intubated via the nasotra-
cheal approach due to the fact that her symptoms
worsened concomitant with the treatment of intrave-
nous chlorpheniramine, ranitidine and hydrocorti-
sone. Her condition improved within the next 48
hours after discontinuation of imidapril and diclofe-
nac without other specific treatment. Due to poten-
tially serious adverse reactions, oral challenge test
with diclofenac was not performed. However, she was
subsequently treated with other NSAIDs, including
aspirin was well tolerated.
DISCUSSION
The reported incidence of ACEI-associated angioe-
dema varies from 0.1―2.2%,1 to as great as 2.8―6%
when ascertained prospectively in some clinical tri-
als.5 ACEI-induced angioedema is the most common
cause of acute angioedema in accidents and emer-
gency hospital departments and up to 20% may be
life-threatening.6 Among the 776 cases of recurrent
angioedema unaccompanied by urticaria in a large
clinical survey in Italy, 85 (11%) were related to treat-
ment with ACEIs.7 Given that 35―40 million people
worldwide are currently taking ACEIs, the number of
people at risk for this side effect is substantial.5
The mechanism of ACEI-induced angioedema is
not yet fully understood because angioedema only
develops in a minority of patients with ACEIs therapy
and its effect is idiosyncratic, not dose-related and
can occur with any ACEIs.2
The mechanism most likely involves increased lo-
cal levels of bradykinin from ACE blockage and de-
creased aminopeptidase P activity in the bradykinin
degradation pathway, in which diminished activity of
dipeptidyl peptidase IV in the substance P degrada-
tion pathway also appears to contribute.1,2,5,8
Of cases of ACEI-related angioedema, 47―72% pre-
sent within the first week of treatment.2 However, re-
cent reports found that less than 25% of patients de-
veloped angioedema within 1 month of starting
ACEIs therapy.1 Onset may be delayed by up to 10
years of treatment,1,5 which could be one reason why
physicians fail to recognize this association. In the
presented patient, the adverse events occurred after a
7 and 2 year period of treatments with enalapril and
imidapril, respectively.
ACEI-induced angioedema has a predilection for
the head and neck and most frequently involves the
tongue and lips, which may lead to life-threatening
airway compromise.1,2,5 Rarely, ACEI-assoicated an-
gioedema may involve visceral organs including
bowel walls, which usually leads to delay in diagnosis
because of confusion with other gastroenterological
pathology.2,5 Pruritus and urticaria also rarely coex-
ist.
Concomitant use of non-steroidal anti-inflammatory
drugs (NSAIDs) is frequently seen in patients with a
history of ACEI-associated angioedema.1 NSAIDs
themselves can cause angioedema by either immu-
nological (IgE-mediated) or non-immunological
(pseudoallergic) reactions, which in the latter are
likely a result of increased leukotriene production
due to cyclooxygenase blockage.6 Therefore, concur-
rent use of NSAIDs may precipitate or worsen an-
gioedema in patients with ACEI therapy.
NSAIDs-induced angioedema is usually accompa-
nied by urticaria and occurs soon after taking the
drugs, contrary to the presented patient, suggesting
that the main cause of these adverse events could be
due to ACEI therapy. However, the role of NSAIDs in
the precipitation of ACEI-induced angioedema in this
patient can not be excluded.
It is generally accepted that ACEIs are contraindi-
cated in patients with a pre-existing history of heredi-
tary or acquired angioedema.2 The rate of angioe-
dema was much higher in ACEI-continued exposure
(18.7 per 100 patient-years) than in those whose use
of the drug was discontinued (1.8 per 100 patient-
years).9 Black Americans have an incidence of ACEI-
associated angioedema 4―5 times higher than that of
white Americans.1,2,5 No sex predominance has been
noted except for patients with gastrointestinal in-
volvement which occurred exclusively in women.10
Smoking, increasing age (>65 years), female gender,
history of drug rash and seasonal allergies are also
associated with increase risk, where as diabetes ap-
pear to be protected from ACEI-associated angioe-
dema.5,11 However, there is no tight association be-
tween ACEI-associated cough and angioedema.5 Pre-
existing narrowing of the oropharyngeal space due to
obesity, previous upper airway surgery or trauma and
patients with sleep apnea may represent a risk factor
for developing upper airway obstruction secondary to
ACEI-related angioedema.2,11
Early recognition and discontinuation of the ACEIs
remain the primary therapy for ACEI-associated an-
gioedema. Immediate treatment depends on the se-
verity of the episode. Primary supportive therapy in-
cludes airway management, with a minority of cases
requiring intubation or cricothyroidotomy. Although
many physicians treat patients with antihistamines,
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steroids and in more severe cases, epinephrine, no
clinical trial has addressed the efficacy of these treat-
ments.5 Patients presenting with angioedema should
be tested for C1 inhibitior function as well as C4, C3,
C1q levels to exclude the possibility of hereditary an-
gioedema or acquired C1-INH deficiency.5,6 Angioe-
dema generally resolved after 24―48 hours and does
not seem to recur if the ACEIs are withdrawn.1,2 Ad-
ministration of FFP has also been effective in the
treatment of resistant cases.1,5
Patients who have experienced angioedema while
taking one ACEI should not be treated with an-
other.1,5 The rate of angioedema in patients taking an-
giotensin II receptor blockers (ARBs) is significantly
lower than the rate of angioedema observed during
ACEIs therapy, as a report showed that only 8% of pa-
tients who previously experienced angioedema from
ACEIs, developed angioedema from ARBs.1 Never-
theless, physicians should use ARBs with caution in
patients who have experienced ACEI-induced angioe-
dema.
In conclusion, ACEIs, particularly, in concomitant
use with NSAIDs should be avoided in patients with a
history of angioedema because continuing admini-
stration tends to lead to more severe attacks.
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